Healthequity (HQY) Cost of Revenue (2013 - 2026)

Healthequity's Cost of Revenue history runs 14 years deep, the most recent figure standing at $98.3 million for Q2 2026.

• On a quarterly basis, Cost of Revenue fell 7.7% year-over-year to $98.3 million in Q2 2026; TTM through Apr 2026 was $392.1 million, a 8.51% decrease from a year earlier, with the FY2026 full-year figure at $400.3 million, down 5.25% from the prior year.
• Cost of Revenue slipped to $98.3 million in Q2 2026 per HQY's latest filing, from $106.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $122.8 million in Q1 2025 and bottomed at $87.9 million in Q3 2022.
• The 5-year median for Cost of Revenue is $96.8 million (2022), against an average of $98.1 million.
• Across the five-year window, Cost of Revenue increased 23.93% in 2025 and declined 13.3% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $88.8 million in 2022, then grew by 1.43% to $90.0 million in 2023, then increased by 14.85% to $103.4 million in 2024, then retreated by 9.0% to $94.1 million in 2025, then climbed by 4.49% to $98.3 million in 2026.
• Per Business Quant, the three latest HQY Cost of Revenue figures stand at $98.3 million (Q2 2026), $106.4 million (Q1 2026), and $94.1 million (Q4 2025).